Harvard Pilgrim Health Care, Inc.

Harvard Pilgrim Health Care, Inc., Office of Sponsored Programs Division, a non-profit healthcare research organization based in Canton, Massachusetts, serves federal agencies as a prime contractor and grant recipient (74% of recent awards as prime) delivering post-market medical product safety surveillance, epidemiological research, pharmacoepidemiology analysis, and vaccine safety monitoring services with minimal set-aside designation across all three delivery channels—federal service contracts, indefinite-delivery contracts, and federal research grants.

The vendor's capability footprint is dominated by work for the FDA's Sentinel System and CDC's Vaccine Safety Datalink, two large-scale federal health surveillance programs. Representative recent contracts include a $55.8 million sole-source bridge contract with FDA (March 2026) for Sentinel 2.0 operations, covering Active Risk Identification and Analysis (ARIA) system operations, real-world evidence data integration, and FISMA compliance support across a patient population exceeding 100 million individuals. A $698 thousand delivery order from CDC (August 2026) funded evaluation of childhood vaccination schedules under Executive Order 14398 within the Vaccine Safety Datalink IDIQ. A $15.85 million delivery order with FDA (August 2023) supported building and sustaining the Sentinel System through ARIA operations and real-world evidence expansion, invoicing $10.9 million in FY2024 across 35.2 FTEs at a derived rate of $149.60 per hour. The vendor also holds a $149 million multiple-award Vaccine Safety Datalink IDIQ with CDC (awarded September 2022, expiration September 2027), supporting post-market surveillance and epidemiological analysis through cost-reimbursable delivery orders.

Customer concentration is pronounced and narrow. The FDA dominates by both award count and dollar value, with 76 prime awards worth $1.18 billion combined potential value across the Sentinel System bridge contract, multiple IDIQ delivery orders, and specialized projects on pregnancy safety, cannabis literature review, and innovation center operations. CDC Pittsburgh accounts for 23 awards worth $701.6 million combined potential value, primarily driven by the Vaccine Safety Datalink IDIQ and related epidemiological research. The National Institutes of Health (across its institutes, particularly the National Heart, Lung, and Blood Institute with 23 awards) and AHRQ round out the top customer set. FDA and CDC together account for approximately 47% of the award count but represent the vast majority of potential dollars, reflecting the scale of the two IDIQs and their task-order structure.

Harvard Pilgrim holds positions on multiple parent vehicles. The most significant is the CDC's Vaccine Safety Datalink IDIQ ($149 million ceiling, multiple-award, through September 2027), under which 13 task orders valued at $224.6 million have been issued. Four FDA-sponsored IDIQs underpin substantial delivery-order activity: HHSF223200910006I carries 19 task orders worth $108.9 million; HHSF223201400030I carries 12 task orders worth $112.1 million; HHSF223200900009I carries 10 task orders worth $4.8 million; and HHSA29020050033I carries 12 task orders worth $13.5 million. These vehicles represent the backbone of the vendor's federal contracting footprint and enable rapid task-order issuance for emerging surveillance, research, and operational needs within the Sentinel and vaccine safety domains.

SCI-reported invoicing across federal service contracts captured in the Service Contract Inventory totaled $79.8 million from FY2022 through FY2025, with FY2025 reflecting $33.3 million invoiced across 49.2 FTEs. The FTE trajectory shows growth from 2.1 FTEs in FY2022 to a peak of 62.4 FTEs in FY2023, then stabilization around 50 FTEs through FY2024 before declining to 34.3 FTEs in FY2025, reflecting the cyclical nature of delivery-order intensity and contract phase-outs. Government-paid hourly rates on SCI-reportable prime contracts ranged from a 10th percentile of $127.92 per hour to a 90th percentile of $408.53 per hour, with a median around $181.07 per hour, indicating a mix of biostatistical, epidemiological, and program-management labor spanning junior to senior technical roles.

The vendor operates as a substantial prime contractor (74% of awards) but incorporates subcontractors across federal health research work. On SCI-reportable prime contracts, subcontractors performed an average of 14% of total contractor hours, with 47 distinct named subcontractors engaged across the portfolio. Recent subcontract roles include contributing epidemiological expertise to Brigham & Women's Hospital on REMS program research (September 2024), providing evidence-based review modeling to Lee Medical Case Review on newborn screening conditions (February 2025), and supporting clinical research at the University of Florida on emerging infections during pregnancy (April 2024). The vendor's subcontract footprint also reflects its position as a sub-recipient on large NIH research grants, where it contributes statistical expertise, data management, and manuscript preparation in support of university prime recipients across cardiovascular, metabolic, maternal health, and genomic research domains.

Federal grant activity is substantial and diverse. Harvard Pilgrim holds prime grants from the National Institute of Child Health and Human Development (NICHD) on medication risk assessment in autoimmune disease during pregnancy ($703 thousand, September 2026), prenatal cell-free DNA screening decision support ($126 thousand, September 2026), and Medicaid coverage of rapid genome sequencing in critically ill infants ($763 thousand, August 2026). It holds prime grants from the National Institute of Environmental Health Sciences ($3.796 million, April 2026) on neighborhood environmental risk factors and kidney function trajectories; from the National Heart, Lung, and Blood Institute on sepsis quality measurement ($1.661 million, August 2026), cardiovascular health trajectories and environmental toxicants ($571 thousand, August 2026), and childhood asthma genetics ($1.51 million, September 2025); and from the National Institute on Aging on reproductive and molecular aging markers ($706 thousand, May 2026). The vendor also serves as a sub-recipient on dozens of NIH, CDC, AHRQ, and SAMHSA-funded research initiatives, contributing biostatistics, epidemiological analysis, data infrastructure, and project management to studies conducted by university prime recipients including Duke University, Harvard Medical School, Boston University, Emory University, and Stanford University.

Activity trends show growth with volatility. Award volume per year has ranged from 17 in FY2022 to 39 in FY2024, with 29 awards documented in FY2026 year-to-date. Combined potential value across all 350 awards stands at $1.9 billion, with $962.3 million obligated (51% of potential). A recompete cliff of $74.7 million in combined potential value is present within the next 24 months, driven by ultimate completion dates on multiple Sentinel System delivery orders and smaller grants approaching their end dates. The vendor's competitive posture is full-and-open (no set-aside designations observed in the award data), positioning it to compete on merit and technical capability rather than protected categories, and its prime-heavy footprint (74%) indicates strong incumbent status across both the FDA and CDC relationships that dominate its revenue.